Get this report today!
Table of Contents
The global market for transplantation products, devices, and pharmaceuticals was valued at nearly $54 billion in 2010 and is projected to grow at an 8.3% compound annual growth rate (CAGR) to reach $80 billion in 2015.
BCC projects that the fastest growing areas of the transplantation market are in tissue typing and tissue products. Tissue typing technologies are expected to grow at a compound annual growth rate (CAGR) of 12% through the forecast period, from a value of $313 million in 2010 to $553 million in 2015. Tissue product development should grow at a CAGR of 10.8%, from 15.6 billion in 2010 to more than $26 billion by 2015.
Alternatives to organ and tissue transplantation continue to add options for cardiac and orthopedic patients, among others. The alternative technologies sector was valued at nearly $29 billion in 2010 and is expected to increase at a 6.9% compound annual growth rate (CAGR) to reach $40 billion in 2015.
REASONS FOR DOING THE STUDY
The objective of this study is to provide an in-depth analysis and forecast of the solid organ and tissue transplantation markets. The focus is on products and procedures used or under development for organ and tissue transplantations, including techniques, therapies, drugs, and diagnostics. Additionally, a market analysis of alternative transplantations with devices such as ventricular assist devices (VAD), total artificial hearts (TAH), and orthopedic replacement and reconstruction devices will be explored.
STUDY GOALS AND OBJECTIVES
Organ transplantation is a dynamic field, with continuing progress in the development of artificial organs and transplantation methods that reduce rejection and infection. There are increased pressures to ensure transplantation methods are as efficient and effective as possible because the need for organ donors far outstrips the availability of organs and tissues
In theory, transplantation is the last therapeutic option available to people in the final stage of an organ or tissue failure. In reality, the supply of organs or tissues is so limited that for the vast majority of people, transplantation is not an option. Despite the lack of organs, the transplantation business continues to innovate through better harvesting and procurement techniques, vastly improved immunosuppression regimens, advanced tissue matching, and effective anti-infective regimens, all of which have helped build the organ and tissue transplantation business to a maturing stage.
This report will focus on procurement and preservation, solid organ transplantation, tissue transplantation, immunosuppressives and other pharmaceuticals, post-transplantation concerns, and alternatives to transplantation. Although the organ transplantation business faces tough challenges, it also offers exciting fields of research and tremendous opportunities to meet growing market demand.
With transplant recipients living much longer, there is a growing need for post-transplant immunosuppression and monitoring. This aspect of the transplantation process will be covered, describing post-transplant drug regimens and patient and graft survival rates.
This report is a valuable tool for anyone assessing the organ and tissue transplantation market and attempting to devise a strategy to successfully compete in this market. This report provides a thorough background on the structure of the organ and tissue transplantation market and the chief challenges and opportunities it faces. It offers the information needed to understand the current market and to address the emerging one.
This is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investing consultants, and others interested in the tissue and transplantation market, its products, its participants, and its future.
SCOPE OF REPORT
This report offers forecasts, by product segment, from 2010 through 2015, including supporting analyses for projections. Product segments covered consist of solid organ (e.g., kidneys, liver, heart-lung, pancreas, intestines) and the tissue transplantation (e.g., bone, skin, cornea, heart valves) markets, along with the pharmaceuticals that accompany each market.
Also included are experimental xenografts and artificial organs; tissue transplants; and cell transplants (e.g., bone marrow, cord blood, peripheral blood, islet cell). The report touches on the use of fetal cells, stem cells, and altered cancer cells.
The arrangement of this report offers an overview of the key elements in the transplantation process: tissue typing, procurement and preservation, immunosuppressants for solid organ and tissue transplants, and postoperative monitoring. International markets are discussed, and information is provided on industry structure and the regulatory environment.
Within each section are discussions of commercialization opportunities for each segment of the market. New or emerging devices, techniques, and pharmaceuticals are highlighted.
Profiles of more than 50 leading companies involved with solid organ transplantation, tissue transplantation, and alternative technologies are included. The report provides information on company placement within the market and strategic analyses of the companies’ available and emerging products.
An appendix featuring various terms and processes used in transplantation is provided at the end of the report.
This report cites autologous products only in relation to their impact on the market for allografts. It does not include blood products, with the exception of peripheral and umbilical cord blood as a source of stem cells.
METHODOLOGIES AND INFORMATION SOURCES
Information for this report was derived from a variety of primary and secondary research sources, including industry analysts, annual reports and Securities and Exchange Commission (SEC) reports, the United Network for Organ Sharing (UNOS), the Organ Procurement and Transplantation Network (OPTN), the Scientific Registry of Transplant Recipients (SRTR), the Center for Medicare and Medicaid Services (CMS), the National Institutes of Health (NIH), the Centers for Disease Control (CDC), other government agencies, and journal articles. Secondary sources include literature searches; product literature; and press releases.
When precise information was not available, a consensus was made using reasonable assumptions and estimates based on historical data.
Peggy S. Lehr is the BCC Research analyst of this report. Ms. Lehr has worked with the publishing arms of for-profit and not-for-profit organizations for more than 25 years, and she specializes in marketing reports on the medical industry. She has contributed several reports on the medical industry for BCC, including reports on the global market for catheters, the sterilization market, reports on pediatric and eldercare markets, and her most recent report on the cardiovascular surgical industry.
Talk to Alison
00 1 718 618 48 97
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
This report on the global apheresis equipment market includes the different facets of therapeutic apheresis, donor apheresis, and the apheresis devices market. The report covers the performance of various ...
Critical Care Market to 2019 - Growth from Factor Concentrates New Indications and Increasing Demand for Albumin in Asia-Pacific Summary GBI Research, the leading business intelligence provider, has ...
Liver Transplantation - Pipeline Review, H1 2013 Summary Global Markets Direct's, 'Liver Transplantation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This ...
... Sample request capitalizing on opportunities in cord blood industry growth (2013 version) summary part 1: global cord blood banking industry - market overview & outlook as of 2013, the cord blood banking ...
... Met which has been consistently reported at 99.9%. This measure does not provide a complete picture of nhsbt s service as it is restricted to adult red blood cell and platelet orders only and includes ...
... And morbidities independent of the primary disease. For patients with low erythropoietin levels relative to the degree of anaemia, erythropoietin may increase haemoglobin sufficiently; otherwise, red blood cell ...
Reportlinker.com © Copyright 2013. All rights reserved.